Literature DB >> 9133904

Consort statement on the reporting standards of clinical trials. MRC uses checklist similar to CONSORT's.

L B O'Toole.   

Abstract

Mesh:

Year:  1997        PMID: 9133904      PMCID: PMC2126461     

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

1.  Clinical trials in orthopaedics research. Part III. Overcoming operational challenges in the design and conduct of randomized clinical trials in orthopaedic surgery.

Authors:  Elena Losina; James Wright; Jeffrey N Katz
Journal:  J Bone Joint Surg Am       Date:  2012-03-21       Impact factor: 5.284

Review 2.  OARSI Clinical Trials Recommendations: Key analytic considerations in design, analysis, and reporting of randomized controlled trials in osteoarthritis.

Authors:  E Losina; J Ranstam; J E Collins; T J Schnitzer; J N Katz
Journal:  Osteoarthritis Cartilage       Date:  2015-05       Impact factor: 6.576

3.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials.

Authors:  D Moher; K F Schulz; D G Altman
Journal:  BMC Med Res Methodol       Date:  2001-04-20       Impact factor: 4.615

4.  Assessing the quality of reports of systematic reviews in pediatric complementary and alternative medicine.

Authors:  David Moher; Karen Soeken; Margaret Sampson; Leah Ben-Porat; Brian Berman
Journal:  BMC Pediatr       Date:  2002-02-27       Impact factor: 2.125

5.  Assessing the quality of reports of randomized trials in pediatric complementary and alternative medicine.

Authors:  David Moher; Margaret Sampson; Kaitryn Campbell; William Beckner; Leah Lepage; Isabelle Gaboury; Brian Berman
Journal:  BMC Pediatr       Date:  2002-02-27       Impact factor: 2.125

6.  Guidance for developers of health research reporting guidelines.

Authors:  David Moher; Kenneth F Schulz; Iveta Simera; Douglas G Altman
Journal:  PLoS Med       Date:  2010-02-16       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.